Molecular mechanisms of adiponectin signaling and PAQR function
脂联素信号传导和 PAQR 功能的分子机制
基本信息
- 批准号:9349368
- 负责人:
- 金额:$ 42.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-15 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAgonistAlpha CellAnimal ModelAntibodiesAreaAttentionBacteriaBindingBiochemicalBiologicalBiologyCardiovascular DiseasesCell membraneCellsCellular AssayCeramidaseCeramidesComplexCrystallizationCrystallographyDataDevelopmentDiabetes MellitusDiabetic mouseDrug usageEngineeringEnvironmentEnzymesEventExhibitsFamilyFamily memberGenetic ScreeningGenetic studyGoalsHormonesHumanHydrolysisIntegral Membrane ProteinLigand BindingLigandsLipidsMediatingMembraneMetabolicMethodsMolecularMusNeurotransmittersNon-Insulin-Dependent Diabetes MellitusObesityOrganismPathway interactionsPhasePlayProductionProtein EngineeringProteinsReagentReceptor SignalingResearchResolutionRoleSecond Messenger SystemsSignal PathwaySignal TransductionSignal Transduction PathwaySignaling MoleculeSphingosineStructureTherapeutic UsesVariantWorkYeastsadiponectincardiovascular healthcytokinedesignhigh throughput screeninginsulin sensitivityinsulin sensitizing drugsnew therapeutic targetoverexpressionpublic health relevancereceptorsmall moleculetargeted treatmenttherapeutic developmenttool
项目摘要
DESCRIPTION (provided by applicant): Transmembrane signaling plays a central role in all of biology, allowing cells to sense and respond to their environment. In humans, integral membrane receptors mediate the effects of hormones, neurotransmitters, cytokines, and a multitude of other signaling molecules. The PAQR receptors are a poorly characterized family of transmembrane receptors, found in organisms ranging from bacteria to humans. Recently, two PAQR receptors have attracted particular attention because they mediate the effects of a protein hormone called adiponectin. Adiponectin has been shown to induce profound insulin-sensitizing and cardioprotective effects in mouse models of diabetes and cardiovascular disease, but little is known regarding the molecular mechanisms of adiponectin signaling. To unravel the molecular details of adiponectin receptor signaling, we will pursue a combination of structural and biochemical studies of adiponectin and its receptors, with the long term goal of developing a detailed molecular understanding of signaling through the adiponectin receptors and broader PAQR family.
描述(由申请人提供):跨膜信号传导在所有生物学中起着核心作用,允许细胞感知和响应其环境。在人类中,整合膜受体介导激素、神经递质、细胞因子和许多其他信号分子的作用。PAQR受体是一个特征不明显的跨膜受体家族,存在于从细菌到人类的生物体中。最近,两种PAQR受体引起了特别的关注,因为它们介导了一种称为脂联素的蛋白质激素的作用。脂联素在糖尿病和心血管疾病小鼠模型中具有显著的胰岛素增敏和心脏保护作用,但脂联素信号转导的分子机制尚不清楚。为了解开脂联素受体信号传导的分子细节,我们将追求脂联素及其受体的结构和生物化学研究的组合,长期目标是通过脂联素受体和更广泛的PAQR家族发展详细的分子理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Kruse其他文献
Andrew Kruse的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Kruse', 18)}}的其他基金
Project 1: Structure, function, and inhibition of SEDS-family peptidoglycan polymerases
项目1:SEDS家族肽聚糖聚合酶的结构、功能和抑制
- 批准号:
10699954 - 财政年份:2022
- 资助金额:
$ 42.38万 - 项目类别:
Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution
通过机器学习和持续进化,使抗体生成快速、可扩展且民主
- 批准号:
10474638 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution
通过机器学习和持续进化,使抗体生成快速、可扩展且民主
- 批准号:
10687279 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution
通过机器学习和持续进化,使抗体生成快速、可扩展且民主
- 批准号:
10021311 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution
通过机器学习和持续进化,使抗体生成快速、可扩展且民主
- 批准号:
10260452 - 财政年份:2020
- 资助金额:
$ 42.38万 - 项目类别:
Molecular mechanisms of sigma receptor signaling
西格玛受体信号传导的分子机制
- 批准号:
9236106 - 财政年份:2017
- 资助金额:
$ 42.38万 - 项目类别:
Molecular mechanisms of sigma receptor signaling
西格玛受体信号传导的分子机制
- 批准号:
9906922 - 财政年份:2017
- 资助金额:
$ 42.38万 - 项目类别:
Molecular mechanisms of adiponectin signaling and PAQR function
脂联素信号传导和 PAQR 功能的分子机制
- 批准号:
9144473 - 财政年份:2015
- 资助金额:
$ 42.38万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 42.38万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 42.38万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 42.38万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 42.38万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 42.38万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 42.38万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 42.38万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 42.38万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 42.38万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 42.38万 - 项目类别: